HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Francesca Micoli Selected Research

Vaccines

2/2022GMMA as a 'plug and play' technology to tackle infectious disease to improve global health: context and perspectives for the future.
11/2021Impact of O-Acetylation on S. flexneri 1b and 2a O-Antigen Immunogenicity in Mice.
10/2021Rationalizing the design of a broad coverage Shigella vaccine based on evaluation of immunological cross-reactivity among S. flexneri serotypes.
1/2021Dissecting the contribution of O-Antigen and proteins to the immunogenicity of Shigella sonnei generalized modules for membrane antigens (GMMA).
1/2021O-Antigen Extraction, Purification, and Chemical Conjugation to a Carrier Protein.
1/2021The role of vaccines in combatting antimicrobial resistance.
1/2021Carbohydrate based meningococcal vaccines: past and present overview.
11/2020Rational Design of a Glycoconjugate Vaccine against Group A Streptococcus.
1/2020Development of a Specific and Sensitive HPAEC-PAD Method for Quantification of Vi Polysaccharide Applicable to other Polysaccharides Containing Amino Uronic Acids.
1/2020Gold nanoparticles morphology does not affect the multivalent presentation and antibody recognition of Group A Streptococcus synthetic oligorhamnans.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Francesca Micoli Research Topics

Disease

6Bacillary Dysentery (Shigellosis)
02/2022 - 06/2020
5Infections
04/2021 - 01/2018
5Typhoid Fever (Typhoid)
01/2020 - 01/2011
3Communicable Diseases (Infectious Diseases)
02/2022 - 01/2019
3Blister (Bulla)
06/2021 - 03/2015
2Bacterial Infections (Bacterial Infection)
01/2021 - 01/2021
2Meningitis
01/2018 - 11/2013
2Sepsis (Septicemia)
01/2018 - 01/2015
1Vaccine-Preventable Diseases
02/2022
1Meningococcal Infections
01/2021
1Hemolysis
11/2020
1Impetigo (Impetigo Contagiosa)
11/2020
1Pharyngitis (Sore Throat)
11/2020
1Haemophilus Infections
01/2020
1Salmonella Infections (Salmonellosis)
10/2018
1Meningococcal Meningitis
11/2013
1Pain (Aches)
01/2011

Drug/Important Bio-Agent (IBA)

19VaccinesIBA
02/2022 - 01/2011
6Polysaccharides (Glycans)IBA
11/2020 - 01/2011
5Proteins (Proteins, Gene)FDA Link
06/2021 - 03/2015
5GlycoconjugatesIBA
01/2021 - 11/2013
4O Antigens (O Antigen)IBA
02/2022 - 10/2018
4glyceryl methyl methacrylateIBA
02/2022 - 01/2018
4AntibodiesIBA
09/2021 - 01/2016
2Immunoglobulin G (IgG)IBA
09/2021 - 01/2018
2Conjugate VaccinesIBA
01/2020 - 01/2011
2AntigensIBA
01/2020 - 01/2018
1LipopolysaccharidesIBA
02/2022
1Virulence Factors (Pathogenicity Factors)IBA
04/2021
1Membrane Proteins (Integral Membrane Proteins)IBA
04/2021
1SiderophoresIBA
04/2021
1Anti-Bacterial Agents (Antibiotics)IBA
01/2021
1CarbohydratesIBA
01/2021
1Interleukin-8 (Interleukin 8)IBA
11/2020
1CRM197 (non-toxic variant of diphtheria toxin)IBA
10/2018
1Bacterial AntigensIBA
01/2018